A Feasibility Study of Transdermal Buprenorphine Versus Transdermal Fentanyl in the Long-Term Management of Persistent Non-Cancer Pain

作者: Farzana Mitra , Shahead Chowdhury , Mike Shelley , Gary Williams

DOI: 10.1111/PME.12011

关键词:

摘要: Objective Buprenorphine and fentanyl transdermal patches are used widely for the management of persistent malignant nonmalignant pain. Buprenorphine patches, both potent opioids, considered to be equally efficacious in managing Various retrospective studies comparing dosage changes buprenorphine pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared effectiveness these patches. The objective present was satisfy this need. Aims This aims compare prospectively efficacy, acceptability, side effects with This would examine feasibility lay groundwork a larger, multicenter where such efficacy safety outcomes two medications can adequately assessed. Design The participants were 46 adults (range 22–80 years.) (mean = 11 years), predominantly lower back Data obtained monthly 12 months. Participants recruited opioid-naive patients, having greater part day night, appropriate treatment After initial assessment, randomly allocated either or patch treatment. then titrated optimal doses medication. Patients adverse unsatisfactory relief treated alternatively discontinued from study. Results Nearly one-third all 41% (8 22) (TDB) group 37.5% 24) (TDF) stopped due unacceptable inadequate relief. remaining showed similar trend improvement intensity, physical activity, sleep, mood throughout study. Significant intensity achieved 6 months stabilized remainder groups. There significant differences over time. However, higher equipotent dose required comparable Compared TDF group, TDB initially experienced relatively less effects. number users suffered local skin reactions. had mood. Thirty-one percent (5 16) 57% 14) needed additional by end 3 By months, 78% (7 9) but comparatively fewer 44% (4 rescue medicines. Both more doctor visits latter half study. Conclusion Thirty total because For those continuing treatment, improvements seen Fifty 43% groups which persisted up Only 11% 13% respectively, sustained after Twenty benefited significantly symptoms depression group. Interestingly, switching seemed increase acceptability preventing tolerance. Confirmation should studied future larger sample.

参考文章(33)
DeAnne F Stolarik, Elizabeth A Nunamaker, Kelly D Garcia, Gary J Jenkins, Junli Ma, Allison J Thiede, Pharmacokinetics of Sustained-Release and Transdermal Buprenorphine in Göttingen Minipigs (Sus scrofa domestica) Journal of The American Association for Laboratory Animal Science. ,vol. 53, pp. 692- 699 ,(2014)
Ramsin Benyamin, Rajive Adlaka, Samir Patel, Andrea M Trescot, Hans Hansen, Scott E Glaser, Standiford Helm, Laxmaiah Manchikanti, Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. ,vol. 11, ,(2008) , 10.36076/PPJ.2008/11/S5
J.G. Kim, S.K. Sohn, D.H. Kim, J.H. Baek, Y.S. Chae, N.Y. Bae, S.Y. Kim, K.B. Lee, Effectiveness of Transdermal Fentanyl Patch for Treatment of Acute Pain Due to Oral Mucositis in Patients Receiving Stem Cell Transplantation Transplantation Proceedings. ,vol. 37, pp. 4488- 4491 ,(2005) , 10.1016/J.TRANSPROCEED.2005.11.038
DL Willems, A Hak, FC Visser, J Cornel, G van der Wal, Patient work in end-stage heart failure: a prospective longitudinal multiple case study: Palliative Medicine. ,vol. 20, pp. 25- 33 ,(2006) , 10.1191/0269216306PM1095OA
Gredes T, Dominiak M, Mordarski S, Zietek M, Lysenko L, Gerber H, The effect of treatment with fentanyl patches on pain relief and improvement in overall daily functioning in patients with postherpetic neuralgia. Journal of Physiology and Pharmacology. ,vol. 60, pp. 31- 35 ,(2009)
Guy Hans, Dominique Robert, Transdermal buprenorphine – a critical appraisal of its role in pain management Journal of Pain Research. ,vol. 2, pp. 117- 134 ,(2009) , 10.2147/JPR.S6503
Maria Caterina Pace, Maria Beatrice Passavanti, Elisa Grella, Luigi Mazzariello, Massimo Maisto, Manlio Barbarisi, Ena Baccari, Pasquale Sansone, Caterina Aurilio, Buprenorphine in long-term control of chronic pain in cancer patients Frontiers in Bioscience. ,vol. 12, pp. 1291- 1299 ,(2007) , 10.2741/2147
Stefan Wirz, Maria Wittmann, Michael Schenk, Andreas Schroeck, Nico Schaefer, Marcus Mueller, Jens Standop, Norbert Kloecker, Joachim Nadstawek, Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine European Journal of Pain. ,vol. 13, pp. 737- 743 ,(2009) , 10.1016/J.EJPAIN.2008.09.005
Walter Gianni, Angelo Raffaele Madaio, Moira Ceci, Elena Benincasa, Gianfranco Conati, Fabrizio Franchi, Giuseppe Galetti, Antonio Nieddu, Bernardo Salani, Stefano Maria Zuccaro, Transdermal Buprenorphine for the Treatment of Chronic Noncancer Pain in the Oldest Old Journal of Pain and Symptom Management. ,vol. 41, pp. 707- 714 ,(2011) , 10.1016/J.JPAINSYMMAN.2010.06.015